首页> 外国专利> new gewebefaktor directed against the thrombomodulin - fusionsproteine as anticoagulants

new gewebefaktor directed against the thrombomodulin - fusionsproteine as anticoagulants

机译:针对血栓调节蛋白的新的gewebefaktor-融合蛋白作为抗凝剂

摘要

This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
机译:本发明涉及新颖的融合蛋白,其由结合组织因子(TF)的靶向蛋白组成,所述靶向蛋白单独或与至少一种选自下组的其他TM结构域组合可操作地连接至血栓调节蛋白(TM)EGF456结构域。 N末端疏水区结构域,EGF123结构域,EGF3和EGF4之间的结构域间环,以及O-糖基化的富含Ser / Thr的结构域或其类似物,片段,衍生物或变体。融合蛋白在损伤部位结合并防止血栓形成的开始。融合蛋白可用于治疗多种血栓形成病症,包括但不限于深静脉血栓形成,弥散性血管内凝血和急性冠状动脉综合征。

著录项

  • 公开/公告号DE60334538D1

    专利类型

  • 公开/公告日2010-11-25

    原文格式PDF

  • 申请/专利权人 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT;

    申请/专利号DE20036034538T

  • 发明设计人 LIGHT DAVID;MCLEAN KIRK;

    申请日2003-04-30

  • 分类号A61K38/19;C12N15/09;A61K38;A61K39/395;A61K48;A61L33;A61P7/02;A61P9/10;A61P29;A61P31/04;A61P35;A61P37/06;A61P43;C07K14/47;C07K14/485;C07K14/745;C07K16/18;C07K16/28;C07K16/36;C07K16/40;C07K19;C12N15/13;C12P21/08;C12Q1/68;

  • 国家 DE

  • 入库时间 2022-08-21 17:46:12

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号